Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole

Vyta Kulpa Oliver1, Angela M Patton, Sudhen Desai

  • 1Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892-1500, USA.

Insights

Carboxyamido-triazole (CAI) inhibits tumor growth by reducing vascular endothelial growth factor (VEGF) and blocking endothelial cell responses. This anti-angiogenic agent disrupts tumor signaling, leading to reduced tumor progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tumor growth relies on angiogenesis, the formation of new blood vessels.
  • Anti-angiogenic agents are crucial for cancer therapy by inhibiting tumor vascularization.
  • Carboxyamido-triazole (CAI) is known to inhibit calcium influx and has shown anti-angiogenic and anti-invasion properties.

Purpose of the Study:

  • To investigate the anti-angiogenic mechanisms of Carboxyamido-triazole (CAI).
  • To determine if CAI affects pro-angiogenic cytokine production and function.
  • To evaluate the impact of CAI on tumor growth and angiogenesis in vivo and in vitro.

Main Methods:

  • In vivo studies using human melanoma xenografts treated with oral CAI.
  • In vitro experiments assessing CAI's effect on A2058 cell secretion of VEGF and IL-8 under various conditions.
  • Analysis of VEGF, HIF-1alpha, and IL-8 gene and protein expression.
  • Matrigel plug assay to measure in vivo vascularization.
  • Human umbilical vein endothelial cell (HUVEC) migration assays.

Main Results:

  • Oral CAI significantly inhibited melanoma xenograft growth and reduced circulating VEGF and IL-8 levels.
  • CAI inhibited VEGF secretion by tumor cells under nutrient-limited and acidic conditions.
  • CAI reduced VEGF and HIF-1alpha expression and decreased in vivo vascular ingrowth.
  • CAI exposure inhibited HUVEC migration towards VEGF.
  • A paradoxical increase in IL-8 secretion and gene expression was observed in vitro, linked to CAI-induced media acidification.

Conclusions:

  • CAI exhibits anti-angiogenic effects by inhibiting tumor cell VEGF production and disrupting endothelial cell responses to VEGF.
  • CAI's mechanism involves downregulating pro-angiogenic factors and interfering with tumor-microenvironment signaling.
  • The study highlights CAI's potential as an anti-angiogenic therapeutic agent for melanoma.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...